MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Total Equity: ₺3,172 Mil (As of Mar. 2026)


IST:MEDTR MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
79 GF Score
Price ₺28.90
GF Value ₺43.68
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is MEDITERA TIBBI MALZEMENAYI VE TICARET AS Total Equity?

MEDITERA TIBBI MALZEMENAYI VE TICARET AS IST:MEDTR +0.14% 79 Total Equity is ₺3,172 Mil as of Mar. 2026. GuruFocus rates IST:MEDTR with a GF Score™ of 79/100 and a GF Value™ of ₺43.68 (Significantly Undervalued). The stock has 5 warning signs investors should review.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS's total equity for the quarter that ended in Mar. 2026 was ₺3,172 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Total Equity Historical Data

* Premium members only.

The historical data trend for MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Total Equity Chart

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 569.37 1,508.86 2,136.44 2,925.44 2,929.43

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,405.74 2,533.72 2,767.87 2,929.43 3,171.60
IST:MEDTR
79GF Score
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3590.527-661.095
=2,929

MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3820.198-648.6
=3,172

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₺3,172 Mil mean?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Total Equity of ₺3,172 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Total Equity is ₺3,172 Mil. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity compare to ABT and SYK?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Total Equity of ₺3,172 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Total Equity is ₺3,172 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺43.68, compared to a current price of ₺28.90 — trading 33.8% below its estimated fair value. The current Total Equity is ₺3,172 Mil. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Total Equity is ₺3,172 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?

Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued. The current stock price of ₺28.90 is trading 33.8% below its estimated GF Value™ of ₺43.68. GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.

Key valuation signals for IST:MEDTR:

  • Total Equity: ₺3,172 Mil
  • GF Value™: ₺43.68 vs. price of ₺28.90 (33.8% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description

Address Sokak No: 29 Tire Organize Sanayi, Ibni Melek OSB Mahallesi, TOSBI Yol 4, Bolgesi Tire, Izmir, TUR, 35900
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
79GF Score

Get the complete analysis for IST:MEDTR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺28.90
Price
₺43.68
GF Value